Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 May;4(1):25-27.
doi: 10.15420/cfr.2018:8:2.

Pharmacological Interventions Effective in Improving Exercise Capacity in Heart Failure

Cristiana Vitale  1 , Spoletini Ilaria  1 , Giuseppe Mc Rosano  1
Affiliations
Review

Pharmacological Interventions Effective in Improving Exercise Capacity in Heart Failure

Cristiana Vitale et al. Card Fail Rev. 2018 May.

Abstract

Heart failure (HF) is characterised by exercise intolerance, which substantially impairs quality of life (QOL) and prognosis. The aim of this review is to summarise the state of the art on pharmacological interventions that are able to improve exercise capacity in HF. Ivabradine, trimetazidine and intravenous iron are the only drugs included in the European Society of Cardiology HF guidelines that have consistently been shown to positively affect functional capacity in HF. The beneficial effects on HF symptoms, physical performance and QOL using these pharmacological approaches are described.

Keywords: Exercise tolerance; heart failure; intravenous iron; ivabradine; trimetazidine.

PubMed Disclaimer

Conflict of interest statement

Disclosure: The authors have no conflicts of interest to declare.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ponikowski P, Voors AA, Anker SD et al. ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–200. doi: 10.1093/eurheartj/ehw128. - DOI - PubMed
    1. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787–847. doi: 10.1093/eurheartj/ehs104. - DOI - PubMed
    1. Piepoli MF, Conraads V, Corrà U et al. Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. Eur J Heart Fail. 2011;13:347–57. doi: 10.1093/eurjhf/hfr017. - DOI - PubMed
    1. Packer M, Narahara KA, Elkayam U et al. Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study. J Am Coll Cardiol. 1993;22:65–72. doi: 10.1016/0735-1097(93)90816-J. - DOI - PubMed
    1. Hampton JR, van Veldhuisen DJ, Kleber FX et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet. 1997;349:971–7. doi: 10.1016/S0140-6736(96)10488-8. - DOI - PubMed